Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 3/20 | 0.67 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.65 |
| ▸ | TYMP | P19971 | 2/20 | 0.50 |
| ▸ | HPRT1 | P00492 | 11/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | VCP | P55072 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1095404 | 1.00 | FGFR1 (0.67) | FGFR1SLC22A6TYMPHPRT1CYP3A4 | |
| SCHEMBL1105226 | 0.89 | FGFR1 (0.53) | FGFR1SLC22A6TYMPHPRT1CYP3A4 | |
| SCHEMBL1096324 | 0.85 | FGFR1 (0.49) | FGFR1SLC22A6TYMPHPRT1CYP3A4 | |
| SCHEMBL1105225 | 0.83 | FGFR1 (0.45) | FGFR1SLC22A6TYMPHPRT1CYP3A4 | |
| SCHEMBL8912289 | 0.81 | FGFR1 (0.53) | FGFR1SLC22A6TYMPHPRT1CYP3A4 | |
| SCHEMBL1135883 | 0.81 | FGFR1 (0.44) | FGFR1SLC22A6TYMPHPRT1CYP3A4 | |
| SCHEMBL14509990 | 0.81 | FGFR1 (0.44) | FGFR1SLC22A6TYMPHPRT1CYP3A4 | |
| SCHEMBL1096328 | 0.80 | FGFR1 (0.55) | FGFR1SLC22A6TYMPHPRT1CYP3A4 | |
| SCHEMBL23292846 | 0.80 | FGFR1 (0.60) | FGFR1SLC22A6TYMPHPRT1CYP3A4 | |
| Cidofovir Anhydrous SCHEMBL151807 | 0.80 | FGFR1 (1.00) | FGFR1SLC22A6TYMPHPRT1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153787-B2 | Azacytosine derivatives useful as antiviral agents | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2012-04-10 | — | — | US | claimed |
| EP-1966226-B1 | AZACYTOSINE DERIVATIVES USEFUL AS ANTIVIRAL AGENTS | LEUVEN K U RES & DEV (BE) | 2010-11-10 | — | — | EP | claimed |
| US-20090005346-A1 | Azacytosine Derivatives Useful as Antiviral Agents | K.U.LEUVEN RESEARCH & DEVELOPMENT (BE) | 2009-01-01 | — | — | US | claimed |
| EP-1966226-A2 | AZACYTOSINE DERIVATIVES USEFUL AS ANTIVIRAL AGENTS | K.U.Leuven Research & Development (BE) | 2008-09-10 | — | — | EP | claimed |
| WO-2007065231-A2 | AZACYTOSINE DERIVATIVES USEFUL AS ANTIVIRAL AGENTS | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2007-06-14 | — | — | WO | claimed |
| US-8153787-B2 | Azacytosine derivatives useful as antiviral agents | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2012-04-10 | — | — | US | disclosed |
| US-8153787-B2 | Azacytosine derivatives useful as antiviral agents | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2012-04-10 | — | — | US | disclosed |
| EP-1966226-B1 | AZACYTOSINE DERIVATIVES USEFUL AS ANTIVIRAL AGENTS | LEUVEN K U RES & DEV (BE) | 2010-11-10 | — | — | EP | disclosed |
| US-20090005346-A1 | Azacytosine Derivatives Useful as Antiviral Agents | K.U.LEUVEN RESEARCH & DEVELOPMENT (BE) | 2009-01-01 | — | — | US | disclosed |
| US-20090005346-A1 | Azacytosine Derivatives Useful as Antiviral Agents | K.U.LEUVEN RESEARCH & DEVELOPMENT (BE) | 2009-01-01 | — | — | US | disclosed |
| EP-1966226-A2 | AZACYTOSINE DERIVATIVES USEFUL AS ANTIVIRAL AGENTS | K.U.Leuven Research & Development (BE) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007065231-A2 | AZACYTOSINE DERIVATIVES USEFUL AS ANTIVIRAL AGENTS | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2007-06-14 | — | — | WO | disclosed |
| WO-2007065231-A2 | AZACYTOSINE DERIVATIVES USEFUL AS ANTIVIRAL AGENTS | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005346-A1 | Azacytosine Derivatives Useful as Antiviral Agents | ITPA, ZC3HAV1, MTAP | FGFR1 4874/4885SLC22A6 2692/4885TYMP 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.